Xolair under the microscope: how well does it work for nasal polyps in real life?
NCT ID NCT05626257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective Xolair is for adults with chronic rhinosinusitis and nasal polyps when used in routine care. 135 patients who were already prescribed Xolair were followed to track side effects and changes in symptoms. The goal was to see how the drug performs outside of strict clinical trial settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Xolair (omalizumab)
What this could lead to
If successful, this could confirm that Xolair is a safe and effective option for managing nasal polyps in everyday medical practice.
What could go wrong
This is a post-marketing surveillance study, not a controlled trial, so results may be less definitive. It also does not test a new treatment, just monitors existing use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Anyang-si, Gyeonggi-do, 14068, South Korea
-
Novartis Investigative Site
Bundang Gu, Gyeonggi-do, 13620, South Korea
-
Novartis Investigative Site
Uijeongbu-si, Gyeonggi-do, 11759, South Korea
-
Novartis Investigative Site
Incheon, Korea, 405 760, South Korea
-
Novartis Investigative Site
Seoul, Korea, 03080, South Korea
-
Novartis Investigative Site
Seoul, Korea, 03312, South Korea
-
Novartis Investigative Site
Seoul, Korea, 07061, South Korea
-
Novartis Investigative Site
Seoul, Korea, 08308, South Korea
-
Novartis Investigative Site
Seoul, Yangcheon gu, 07985, South Korea
-
Novartis Investigative Site
Daegu, 705 718, South Korea
-
Novartis Investigative Site
Gyeonggi-do, 14353, South Korea
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Seoul, 06351, South Korea
-
Novartis Investigative Site
Seoul, 07804, South Korea
-
Novartis Investigative Site
Seoul, 2447, South Korea
-
Novartis Investigative Site
Suwon, 16247, South Korea